Slow N-acetyltransferase 2 status leads to enhanced intrastriatal dopamine depletion in 6-hydroxydopamine-lesioned rats

Experimental Neurology

Volumn 187, Issue 1, 2004, Pages 199-202

  Grundmann, M ^a   Earl, C D ^a   Sautter, J ^a   Henze, C ^a   Oertel, W H ^a   Bandmann, O ^a,b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

6 Hydroxydopamine; N Acetyltransferase 2; Wistar Kyoto

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; DOPAMINE; NEUROTOXIN; OXIDOPAMINE;

ACETYLATOR PHENOTYPE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; NERVE ENDING; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE; SUBSTANTIA NIGRA;

ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; CELL COUNT; DOPAMINE; DRUG RESISTANCE; MALE; NEOSTRIATUM; OXIDOPAMINE; RATS; RATS, INBRED F344; RATS, INBRED WKY; SPECIES SPECIFICITY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 1842814225     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2004.01.001     Document Type: Article

References (17)

1. Altar C.A., Marien M.R., Marshall J.F. Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J. Neurochem. 48:1987;390-399.
2. Bandmann O., Vaughan J., Holmans P., Marsden C.D., Wood N.W. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet. 350:1997;1136-1139.
3. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3:2000;1301-1306.
4. Blum D., Torch S., Lambeng N.et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65:2001;135-172.
5. Boukouvala S., Price N., Sim E. Identification and functional characterization of novel polymorphisms associated with the genes for arylamine N-acetyltransferases in mice. Pharmacogenetics. 12:2002;385-394.
6. Carman L.S., Gage F.H., Shults C.W. Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior. Brain Res. 553:1991;275-283.
7. Chan D.K.Y., Lam M.K.P., Wong R., Hung W.T., Wilcken D.E.L. Strong association between N-acetyltransferase 2 genotype and PD in Hong Kong Chinese. Neurology. 60:2003;1002-1005.
8. Glinka Y., Gassen M., Youdim M.B. Mechanism of 6-hydroxydopamine neurotoxicity. J. Neural Transm., Suppl. 50:1997;55-66.
9. Grant D.M., Goodfellow G.H., Sugamori K.M., Durette K. Pharmacogenetics of the human arylamine N-acetyltransferases. Pharmacology. 61:2000;204-211.
10. Hein D.W., Doll M.A., Fretland A.J.et al. Rodent models of the human acetylation polymorphism: comparisons of recombinant acetyltransferases. Mutat. Res. 376:1997;101-106.
11. Höglinger G.U., Feger J., Prigent A.et al. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84:2003;491-502.
12. Kulich S.M., Chu C.T. Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J. Neurochem. 77:2001;1058-1066.
13. Ogawa M. Biochemical, molecular genetic and ecogenetic studies of polymorphic arylamine N-acetyltransferase (NAT2) in the brain. Fukuoka Igaku Zasshi. 90:1999;118-131.
14. Przedborski S., Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov. Disord. 13(Suppl. 1):1998;35-38.
15. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience. 59:1994;401-415.
16. Walt J.M., Martin E.R., Scott W.K.et al. Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. Neurology. 60:2003;1189-1191.
17. Warner T.T., Schapira A.H. Genetic and environmental factors in the cause of Parkinson's disease. Ann. Neurol. 53(Suppl. 3):2003;S16-S23.